Michael E. Bigler
6Patents
2h-index
12Co-inventors
40Inventor score
Filing activity: Mar 10, 2008 → Sep 20, 2016
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9709568B2 | Antibodies that bind to human programmed death ligand 1 (PD-L1) | Physics | 8 | Active |
| US8153134B2 | Anti-MDL-1 antibodies | Chemistry; Metallurgy | 6 | Active |
| US8236309B2 | Use of bispecific antibodies to regulate immune responses | Human Necessities | 1 | Active |
| US10647771B2 | Antibody that binds to human programmed death ligand 2 (PD-L2) and uses thereof | Physics | 1 | Active |
| US8263070B2 | Methods of modulating CD200 receptors | Chemistry; Metallurgy | 0 | Active |
| US8178094B2 | Methods for inhibiting tumor growth or reducing metastatic burden in a subject by administering FDF03 antibodies | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.